“…Prior registry-based studies evaluated outcomes of post-AA MN patients after SCT, with comparable OS for post-AA versus de novo MDS, and better OS compared to other types of secondary MDS. 12-14 However, these analyses were restricted to transplanted patients and did not include data on pretransplant patient management. Cytotoxic chemotherapy has been linked to increased rates of hematologic and extra-hematopoietic toxicities in inherited BMF.…”